摘要
目的探讨头孢曲松钠联合苄星青霉素治疗潜伏梅毒的临床疗效。方法选取南京市第二医院皮肤科门诊2019年1月至2021年12月收治的潜伏梅毒患者247例,按抽签法随机分为观察组(119例)和对照组(128例)。两组患者均予苄星青霉素240万U肌肉注射,每周1次,连续3次;观察组患者加用头孢曲松钠1.0g静脉滴注,每日1次,连续10 d。结果观察组早期潜伏梅毒患者治疗后的血清RPR及RPR转阴率及总有效率均显著优于对照组(P<0.05),观察组晚期潜伏梅毒患者治疗后的血清非梅毒螺旋体血清学试验(RPR)及RPR转阴率及总有效率均显著优于对照组(P<0.05)。血清RPR滴度均为1∶8时,观察组患者的治疗转阴率及总有效率均显著优于对照组(χ^(2)=5.90,7.26,P<0.05)。结论头孢曲松钠联合苄星青霉素治疗早期潜伏梅毒疗效优于单一用药,对提高晚期潜伏梅毒治疗总有效率有积极意义。
Objective To investigate the clinical efficacy of ceftriaxone sodium combined with benzathine benzylpenicillin in the treatment of latent syphilis.Methods A total of 247 patients with latent syphilis admitted to the Department of Dermatology of Nanjing Second Hospital from January 2019 to December 2021 were selected and randomly divided into the observation group(119 cases)and the control group(128 cases)by drawing method.Both groups were given intramuscular injection of 2.4 million U of benzathine benzylpenicillin,once a week for three weeks.On this basis,patients in the observation group were given intravenous drip of 1.0 g of ceftriaxone sodium,once a day for 10 d consecutively.Results The serum RPR,RPR seroconversion rate and total effective rate in the observation group were significantly better than those in the control group after treatment(P<0.05).The serum non syphilitic spirochete serological test(RPR),RPR seroconversion rate,and total effective rate in the observation group were significantly better than those in the control group(P<0.05).When the serum RPR titer was 1∶8,the treatment conversion rate and total effective rate in the observation group were significantly better than those in the control group(χ^(2)=5.90,7.26,P<0.05).Conclusion Ceftriaxone sodium combined with benzathine benzylpenicillin is more effective than single drug in the treatment of early latent syphilis,and has a positive significance in improving the overall effective rate.
作者
闫宁
于晓云
李子海
刘文丽
YAN Ning;YU Xiaoyun;LI Zihai;LIU Wenli(Department of Dermatology,Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine·Nanjing Second Hospital,Nanjing,Jiangsu,China 210003;Department of Dermatology,People's Hospital of Liuhe District,Nanjing,Jiangsu,China 211500)
出处
《中国药业》
CAS
2023年第S02期42-44,共3页
China Pharmaceuticals